Insilico Medicine / insilico.com
AI-powered drug discovery company that uses generative AI and deep learning to design novel drug candidates, predict target biology, and accelerate the path from target identification to clinical trials.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
Yes
Open source
No
Platforms
2
Insilico Medicine is one of the leading AI drug discovery companies, using generative AI and deep learning to design novel drug candidates from scratch rather than only screening existing compound libraries. Its Chemistry42 platform generates novel molecule structures optimised for specific target proteins and desired drug properties including potency, selectivity, and ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles.
The most notable validation of Insilico's approach is INS018_055, a novel anti-fibrosis drug candidate discovered and designed entirely by AI with no prior pharmacological knowledge used in the design process. This compound entered Phase 2 clinical trials in 2023, making Insilico the first company to advance a fully AI-designed drug candidate to this stage.
Target ID uses AI to identify novel biological targets for specific diseases by analysing genomic, proteomic, and clinical data. PandaOmics, the target identification platform, has suggested novel targets for diseases including Parkinson's, ALS, and kidney fibrosis.
Insilico partners with pharmaceutical companies including Pfizer, Sanofi, and Pfizer to apply its AI platform to their drug discovery programmes. The company is listed on NASDAQ (ILAB), providing financial transparency.
Insilico Medicine runs as ml platform software built around data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api, with API access for teams that want to embed it into their own products.
Recent YouTube videos cached from the backend so this page stays fast and fresh.
The capabilities that matter most for teams evaluating Insilico Medicine.
Generative AI platform that designs novel drug candidate molecules from scratch, optimised for specific target proteins and desired ADMET and potency properties.
PandaOmics analyses genomic, proteomic, and clinical data to identify novel biological targets for diseases including Parkinson's, ALS, and kidney fibrosis.
INS018_055, a novel anti-fibrosis compound discovered and designed entirely by AI, entered Phase 2 clinical trials — the most advanced AI-designed drug in human trials.
Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.
Model
Enterprise
Starting price
Free
Free trial
No
Recursion Pharmaceuticals is a direct competitor in AI drug discovery with biological data focus. Schrödinger is a computational chemistry platform used in drug discovery. AbSci provides AI for antibody drug design. Exscientia is a strong European competitor.
A side-by-side look at the closest alternative in this category.
Key facts about model providers, platforms, and team support.
Model Provider
Insilico
Models
Chemistry42, PandaOmics
Platforms
Web, API
Deployment
SaaS, Enterprise partnership
Integrations
Major pharmaceutical ERP and research systems, API
Team Collaboration
No
Launch Year
2014
Compliance signals and data-handling notes as reported by the vendor.
Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.
Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.
Editorial Verdict
Insilico Medicine is the most validated AI drug discovery company with Phase 2 clinical evidence, best positioned as a pharmaceutical research partner for companies wanting to apply AI to novel target-based drug design.
Last verified July 24, 2026.
Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.
Pharmaceutical partnership programmes. No public pricing or individual access. Publicly traded on NASDAQ (RXRX).
Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.
Enterprise research data handling agreements. GDPR compliant. Publicly traded company (RXRX) with standard public company disclosures.
Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.
Recursion processes biological research data under enterprise partnership data handling agreements.
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Insilico Medicine and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
